Executive Summary

The market for GLP-1 therapies has shifted from a specialist niche to a mass-scale category, and the information behavior of the physicians who prescribe them has changed with it. Analysis published by IQVIA describes a healthcare professional (HCP) population that follows a fast-moving therapeutic area largely through digital sources, and argues that conventional broad-reach engagement models no longer produce differentiated results in a saturated information environment.

Three developments stand out. First, prescribing activity has scaled: IQVIA cites analysis indicating that more than 500,000 healthcare professionals wrote prescriptions for GLP-1 therapies in 2025 alone, while J.P. Morgan research referenced in the same analysis estimates that as many as 30 million Americans — close to 9% of the population — could be eligible for or using the therapies by 2030. Second, engagement is heavily concentrated: digital research activity follows a long-tail distribution in which a small top decile of physicians accounts for a disproportionate share of activity. Third, market events move behavior: clinical trial readouts, regulatory decisions and pricing announcements repeatedly generate spikes in physician research, according to IQVIA's AIM data.

For pharmaceutical companies, the implication is that competitive advantage is shifting from message volume toward timing, segmentation and measurement deeper in the commercial funnel — activation, conversion and adherence rather than top-of-mind awareness alone.

Introduction

Obesity treatment has become one of the largest and most closely watched segments of the global pharmaceutical market. As GLP-1 receptor agonists moved into mainstream clinical use, public awareness rose sharply, patient demand increased and the number of companies competing for physician attention expanded. The result is a category in which the traditional commercial playbook — broad awareness campaigns, generalist messaging and high-frequency reach — is being tested against a physician audience that has already been reached.

IQVIA's assessment of the category, published in March 2026, examines how HCP digital behavior is reshaping engagement strategy. Its central observation is that the constraint on commercial performance is no longer awareness but attention, and that understanding when and how physicians research a therapy has become as important as what companies tell them.

Background

Several structural changes created the current environment.

Clinical evidence expanded the category's scope. Results from the SURMOUNT-2 trial, published in The Lancet, showed approximately 15% weight loss with tirzepatide, a finding IQVIA's data associates with a surge in physician research activity. Subsequent developments — including the U.S. Food and Drug Administration's resolution of a prolonged semaglutide shortage, pricing agreements under a Most Favored Nation framework that reduced GLP-1 costs and enabled Medicare coverage of obesity treatments, and the approval of an oral formulation — each coincided with renewed spikes in HCP digital engagement.

At the same time, the prescriber base broadened well beyond endocrinology, drawing in primary care, cardiology, gastroenterology and other specialties. The eligible patient population is also large and still expanding, which changes the economics of targeting: when both the provider and patient universes are measured in the millions, segmentation precision matters more than reach.

Main Analysis

From awareness to behavioral signals

IQVIA's analysis distinguishes between traditional engagement metrics and behavioral indicators such as research intensity, intent signals and prescribing patterns. With awareness already high, the value of differentiating between high-potential and low-potential physician segments using audience quality metrics alone declines. The analytical emphasis instead falls on identifying which clinicians are actively researching, questioning or signalling early interest in specific mechanisms of action, dosing options or comorbidity profiles.

This reflects a practical problem for commercial teams. The digital marketplace around GLP-1 therapies is crowded, and the space available for a brand to distinguish itself has compressed. Targeting the small share of physicians that generate most research activity — while maintaining lighter-touch contact with the wider base — is presented as a more efficient allocation of resources than uniform high-frequency outreach.

Lifecycle determines tactics

IQVIA draws a clear distinction between pre-launch and in-market strategy. For pipeline products, the analytical task is to identify early adopters through digital engagement trends and to shape educational content around their specific clinical interests. For products already on the market, the priority shifts to defending and expanding share through competitive intelligence — monitoring competitor trial activity and molecule mentions, and responding with comparative data or patient support resources through coordinated digital and in-person channels.

The reference also flags a newer consideration: content structure. IQVIA argues that supporting publications should be formatted so that they remain discoverable through AI-assisted search tools, a requirement that did not exist when most medical communication strategies were designed.

Timing as a commercial variable

One of the more consequential findings concerns event-driven behavior. Physician research activity rises measurably around major category developments, including trial publications, guideline updates, regulatory approvals and pricing changes. IQVIA's position is that brands can anticipate and prepare for these windows rather than react to them, sequencing touchpoints before, during and after high-attention events to extend engagement and sustain clinical understanding as competition intensifies.

What the data does not resolve

Digital engagement is a proxy, not an outcome. Higher research activity does not automatically translate into prescribing, and the analysis acknowledges that measurement should extend to activation, conversion and adherence. For commercial and medical teams, the analytical challenge is to connect upstream behavioural signals to downstream clinical and commercial results without overstating the causal link.

Global Significance

The shift has implications well beyond the United States, where most of the cited data originates.

For the global pharmaceutical industry, commercial operating models built around field-force reach and mass-media awareness are being reweighted toward data infrastructure, analytics capability and content operations. Companies that invest in physician-level behavioural data and predictive modelling may gain a structural advantage in launching or defending products in crowded categories.

For health systems and payers, the expansion of the eligible population raises questions of affordability, access and coverage design. Pricing agreements and coverage decisions have already demonstrated that policy choices can alter physician information-seeking behavior within days, which suggests that reimbursement policy is itself a communications event.

For technology providers, the category illustrates how quickly analytics, intent modelling and AI-mediated content discovery have moved from support functions to core commercial infrastructure. This has consequences for data governance, since physician-level targeting is subject to differing privacy, promotional and transparency rules across jurisdictions — a constraint that shapes how far U.S.-developed engagement models can be exported.

For other therapeutic areas, the obesity market functions as a test case. IQVIA notes early indications that the same practices are beginning to appear elsewhere, which would extend the model across specialty and primary care sectors globally.

Strategic Insights

Segmentation is becoming predictive rather than descriptive. The analytical frontier is not classifying physicians by past prescribing volume but anticipating which segments will adopt new mechanisms of action, oral formulations or multi-indication therapies as they enter the market.

Timing is a measurable asset. Because research activity clusters around news events, the ability to detect and respond to windows of elevated curiosity is a competitive capability — one that depends on data latency as much as on creative execution.

Funnel depth is replacing funnel width. Awareness metrics are of limited strategic value in a category where awareness is close to universal. Activation, switching and adherence metrics carry more information about real commercial movement.

Competitive intelligence is now continuous. Monitoring competitor trial activity and molecule mentions, and preparing differentiated responses in advance, is a standing requirement rather than a periodic exercise.

Risk sits in the data layer. Over-reliance on behavioural proxies, uneven data quality across markets and tightening privacy regulation are the principal constraints on scaling these approaches internationally. Companies that treat compliance and data quality as design requirements rather than afterthoughts are likely to move faster over time.

Future Outlook

The next three to ten years are likely to bring several structural changes.

Competition will intensify as oral GLP-1 therapies and treatments targeting multiple comorbidities enter the market. A larger number of brands competing for the same physician attention will compress differentiation further, strengthening the case for behavioural segmentation and precision outreach.

Patient volume will continue to scale. If estimates of roughly 30 million eligible or active U.S. users by 2030 prove accurate, adherence and persistence management will become a central commercial and clinical concern, and engagement strategies will need to extend beyond the prescribing decision to long-term patient support.

AI will shape both sides of the exchange. Physicians increasingly discover medical content through AI-assisted tools, and companies increasingly use predictive models to prioritise outreach. The result is likely to be a rebalancing of medical communication toward structured, machine-readable content and away from purely persuasive formats.

Policy will remain a primary variable. Coverage decisions, pricing frameworks and regulatory approvals have repeatedly proven capable of resetting physician attention within short periods. Companies that treat policy monitoring as part of commercial intelligence rather than as a separate function may be better positioned to respond.

Beyond obesity, the engagement model tested in this category is likely to diffuse into oncology, cardiology and immunology, where similar pressures on attention and similar volumes of clinical data already exist.

Conclusion

The GLP-1 category has become a case study in how a therapeutic area's commercial logic changes once awareness saturates and evidence accumulates faster than any individual physician can absorb. Digital channels are not simply an additional route to physicians; they are now the primary environment in which clinical interest forms and is expressed.

The evidence assembled in IQVIA's analysis points in one direction: competitive advantage in this market depends on detecting interest early, understanding who is generating it, and engaging at the moment it peaks. That is a data and operational problem as much as a communications one — and it is a problem that pharmaceutical companies in other therapeutic areas are likely to face within the next decade.

Key Takeaways

• GLP-1 therapies have moved into mainstream clinical practice, with more than 500,000 U.S. healthcare professionals writing prescriptions in 2025 alone, according to IQVIA's cited analysis.
• Physician research activity is concentrated in a small top decile of HCPs, making precise segmentation more valuable than broad reach.
• Awareness has saturated; measurement is shifting toward activation, conversion and adherence.
• Clinical, regulatory and pricing events produce measurable spikes in HCP digital engagement, making timing a commercial variable.
• Go-to-market approaches are being differentiated by product lifecycle, from pre-launch adopter identification to in-market competitive response.
• The model has global implications for data governance, market access and medical communication, though regulatory frameworks differ by jurisdiction.
• Early indications suggest similar approaches are spreading to other therapeutic areas.

Topics and Keywords

Global News; International Business; Global Economy; Pharmaceutical Industry; Artificial Intelligence; Technology; Healthcare; Digital Economy; Business Strategy; Public Policy; Investment; Global Markets; International Trade; Innovation; Economic Development; Future Trends.

Sources

• IQVIA, "HCP Digital: Using the Digital World as an Advantage": https://www.iqvia.com/locations/united-states/blogs/2026/03/hcp-digital-using-the-digital-world-as-an-advantage
• J.P. Morgan Global Research, obesity drug market analysis: https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs
• Eli Lilly and Company, SURMOUNT-2 results published in The Lancet: https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-2-results-published-lancet-show-tirzepatide